Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
Sign in with Google
ENTITY
Celltrion Inc (068270 KS)
Watchlist
545
Analysis
Health Care
•
South Korea
Celltrion Inc. produces and sells biosimilar products and also provides consignm ent processing service for other companies. The Company's main product is Abata cept which is for arthritis treatment
more
Watchlist
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
Celltrion Inc
•
26 Feb 2025 00:30
Celltrion (068270 KS): Record High Sales in 4Q; Sequentially Weaker Profit; Solid Outlook for 2025
Celltrion reported 178% revenue growth in 4Q24. The company guided for 2025 revenue of KRW5.0T, up 43% YoY. Operating profit margin is expected to...
Tina Banerjee
Follow
246 Views
Share
bullish
•
Celltrion Inc
•
13 Dec 2024 11:06
Celltrion: Meaningful Increase in Cash and Stock Dividends
Celltrion Inc announced meaningful increase in dividends. Celltrion will pay out stock dividend of 0.05 for shareholders as of record in 2024 (up...
Douglas Kim
Follow
452 Views
Share
bullish
•
Celltrion Inc
•
13 Dec 2024 09:09
Celltrion Inc (068270 KS): Record High Sales in 3Q; Pipeline Progress Entails Long-Term Growth
Celltrion has announced dividend of KRW750 per share and one bonus shares for every 20 shares held. The record date for dividend payment and bonus...
Tina Banerjee
Follow
656 Views
Share
bearish
•
Celltrion Inc
•
17 Sep 2024 09:14
Celltrion Inc (068270 KS)– Is the Sell-Side’s Bullishness Justified?
Biosimilar market is expected to grow much faster than generic drug market, but profitability will be a challenge. Celltrion’s guidance is too...
daaimon
Follow
333 Views
Share
bearish
•
Korea Stock Exchange KOSPI 200
•
25 Feb 2025 09:46
Korea: Short Selling Is Back in March; Trade Ideas
Short selling in Korea resumes on 31 March. Shorts have plummeted and will increase. Foreign investors have been sellers for the last 8 months....
Brian Freitas
Follow
772 Views
Share
For Institutional Investors and Financial Services
For Corporate IR and Strategy
For Private Wealth Intermediaries
Pricing
Who We Are
Careers
FAQs
Research Provider Solutions
Syndicate your Publications
Compliance
Terms of Use
Privacy Policy
Press Kit
RSS Feeds
Request a Free Trial
Avail a Transition Account
Guest Posts on Smartkarma
Other Enquiries
Join TL;DR Community
Free Weekly Newsletters
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.49.0
x